Guidance
3 Other information
3 Other information
3.1 Scope and how this guideline was developed
The scope for the original NICE clinical guideline 81 (published February 2009) covers the recommendations labelled [2009], and the scope for the updated NICE clinical guideline covers the recommendations labelled [new 2014].
Groups that will be covered
-
Women and men with invasive adenocarcinoma of the breast of clinical stage 4 (that is, with known metastatic disease).
Groups that will not be covered
-
Women and men with invasive adenocarcinoma of the breast of clinical stages 1, 2 and 3 (this is covered by the NICE guideline on 'Early and locally advanced breast cancer: diagnosis and treatment').
-
Women and men with metastases to the breast from other primary tumours.
-
Women and men with rare breast tumours (for example, angiosarcoma, lymphoma).
-
Women and men with benign breast tumours (for example, fibroadenoma, benign phyllodes tumours).
|
How this guideline was developed NICE's Clinical Guidelines Update Programme updated this guideline. These guidelines are updated using a standing committee of healthcare professionals and lay members from a range of disciplines and localities. For the duration of the update the core members of the committee are joined by up to five additional members who are have specific expertise in the topic being updated. All of the standing members and the topic specific members are fully voting members of the committee. The methods and processes for developing NICE clinical guidelines are described in The guidelines manual. The interim process and methods guide for the clinical guideline rapid updates pilot programme (2013) are described here. |
3.2 Related NICE guidance
Details are correct at the time of publication of the guideline (July 2014). Further information is available on the NICE website.
Published
General
-
Patient experience in adult NHS services. NICE clinical guidance 138 (2012).
-
Medicines adherence. NICE clinical guidance 76 (2009).
Condition-specific
-
Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. NICE technology appraisal guidance 295 (2013).
-
Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE clinical guideline 164 (2013).
-
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 263 (2012).
-
Fulvestrant for the treatment of locally advanced or metastatic breast cancer. NICE technology appraisal guidance 239 (2011).
-
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 214 (2011).
-
Early and locally advanced breast cancer: diagnosis and treatment. NICE clinical guideline 80 (2009).
-
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (update of technology appraisal guidance 87) NICE technology appraisal guidance 161 (2008).
-
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance 160 (2008).
-
Gemcitabine for the treatment of metastatic breast cancer. NICE technology appraisal guidance 116 (2007).
-
Improving supportive and palliative care for adults with cancer. Cancer service guidance (2004).
-
Improving outcomes in breast cancer – manual update. Cancer service guidance (2002).
-
Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE technology appraisal guidance 34 (2002).
Under development
NICE is developing the following guidance (details available from the NICE website):
Referral guidelines for suspected cancer (update). NICE clinical guideline. Publication expected May 2015.
Standing Committee A and NICE project team
3.3 Standing Committee A
The Committee members listed are those for the 2014 update. For the composition of (the) previous Guideline Development Group, see the full guideline.
Standing committee members
Damien Longson, Chair
Consultant Liaison Psychiatrist, Manchester Mental Health and Social Care Trust
Susan Bewley, Vice Chair
Honorary Professor of Complex Obstetrics, Women's Academic Health Centre, St Thomas' Hospital
Catherine Briggs
GP Principal, Bracondale Medical Centre, Stockport
John Cape
Director of Psychological Therapies Programmes, University College London
Alun Davies
Professor of Vascular Surgery and Honorary Consultant Surgeon, Charing Cross & St Mary's Hospital & Imperial College NHS Trust
Alison Eastwood
Senior Research Fellow, Centre for Reviews and Dissemination, University of York
Sarah Fishburn
Lay Member
Amanda Gibbon (until March 2014)
Lay Member
Jim Gray
Consultant Medical Microbiologist, The Birmingham Children's Hospital NHS Foundation Trust
Nuala Lucas
Consultant Anaesthetist, Northwick Park Hospital, Middlesex
Kath Nuttall
Director, Lancashire & South Cumbria Cancer Network (- April 2013)
Tilly Pillay
Consultant Neonatologist, Staffordshire, Shropshire and Black Country Newborn Network, Royal Wolverhampton Hospitals Trust
Nick Screaton
Radiologist, Papworth Hospital NHS Foundation Trust
Lindsay Smith
Principal in General Medical Practice, Somerset PCT
Philippa Williams (from March 2014)
Lay Member
Sophie Wilne
Paediatric Oncologist, Nottingham Children's Hospital